Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.79 USD | -0.40% | -3.02% | -52.76% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 65% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-52.76% | 2.44B | C+ | ||
-0.09% | 42.12B | B | ||
+49.62% | 42.05B | A | ||
-4.96% | 29.18B | C | ||
+11.18% | 26.02B | B- | ||
-21.95% | 18.9B | B | ||
+8.61% | 13.21B | B+ | ||
+24.73% | 12.17B | B+ | ||
+28.31% | 12.16B | C+ | ||
-6.26% | 11.42B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACAD Stock
- Ratings ACADIA Pharmaceuticals Inc.